/PROK

ProKidney Corp

PROK

$1.80USD↓-2.17%-0.04 today

MARKET CAP

544.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1

$3

AI Summary

Stalk

StalkMedium

PROK remains in a high-confidence Stage 2 advancing phase with strong momentum signals from the recent breakout and structural repair. However, price is currently extended above the 9/21/50 EMAs with RSI and Options Score into overbought territory, increasing the risk of a near-term pullback. The medium-term bias stays bullish based on rising EMAs, volume expansion on advances, and multiple mean-reversion and continuation patterns. Execution is best deferred—await a pullback into the rising 9/21 EMA cluster and the prior breakout area around the former resistance zone for confirmation before initiating exposure.

↑Complete enrollment of 320 patients in Phase 3 PROACT trial; topline data due Q2 2027
↑$181.6 million cash reserves fund operations through mid-2027, enabling pipeline advancement
↓Q2 2026 revenue $0.15 million, missing estimates by 31.8%, highlighting weak commercial dynamics

Full analysis →

Buying

3

institutions

Selling

5

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	5.20 M	10.60 M	+3.81 M	+327.0%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	1.10 M	2.24 M	+-151.39 K	+0.2%	0.00%
MM Millennium Management LLC Q2 2026	SELL	1.05 M	2.15 M	+-1.22 M	-47.1%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	115.50 K	235.62 K	+93.20 K	+490.3%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	32.12 K	60.72 K	+31.37 K	+4856.4%	0.00%
WP Woodline Partners LP Q2 2026	SELL	0.00	0.00	+-1.00 M	-100.0%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	0.00	0.00	+-65.58 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-64.15 K	-100.0%	0.00%